- Home
- TXMD vs ZDAI Comparison
TXMD vs ZDAI Comparison
Compare TXMD & ZDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXMD
- ZDAI
- Stock Information
- Founded
- TXMD 2008
- ZDAI 2022
- Country
- TXMD United States
- ZDAI Hong Kong
- Employees
- TXMD N/A
- ZDAI N/A
- Industry
- TXMD Biotechnology: Pharmaceutical Preparations
- ZDAI General Bldg Contractors - Nonresidential Bldgs
- Sector
- TXMD Health Care
- ZDAI Consumer Discretionary
- Exchange
- TXMD Nasdaq
- ZDAI Nasdaq
- Market Cap
- TXMD 12.7M
- ZDAI 13.5M
- IPO Year
- TXMD N/A
- ZDAI 2024
- Fundamental
- Price
- TXMD $1.06
- ZDAI $0.59
- Analyst Decision
- TXMD
- ZDAI
- Analyst Count
- TXMD 0
- ZDAI 0
- Target Price
- TXMD N/A
- ZDAI N/A
- AVG Volume (30 Days)
- TXMD 17.5K
- ZDAI 6.1M
- Earning Date
- TXMD 11-11-2025
- ZDAI 09-30-2025
- Dividend Yield
- TXMD N/A
- ZDAI N/A
- EPS Growth
- TXMD N/A
- ZDAI N/A
- EPS
- TXMD N/A
- ZDAI N/A
- Revenue
- TXMD $2,559,000.00
- ZDAI $19,275,673.00
- Revenue This Year
- TXMD $427.09
- ZDAI N/A
- Revenue Next Year
- TXMD N/A
- ZDAI N/A
- P/E Ratio
- TXMD N/A
- ZDAI N/A
- Revenue Growth
- TXMD 156.93
- ZDAI 43.16
- 52 Week Low
- TXMD $0.70
- ZDAI $0.37
- 52 Week High
- TXMD $2.44
- ZDAI $107.36
- Technical
- Relative Strength Index (RSI)
- TXMD 40.43
- ZDAI 60.49
- Support Level
- TXMD $1.06
- ZDAI $0.53
- Resistance Level
- TXMD $1.14
- ZDAI $0.89
- Average True Range (ATR)
- TXMD 0.05
- ZDAI 0.08
- MACD
- TXMD -0.00
- ZDAI 0.02
- Stochastic Oscillator
- TXMD 5.26
- ZDAI 40.67
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
About ZDAI Primega Group Holdings Limited Ordinary Shares
Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.